DATE: 30 September 2024 CATEGORY: PRESS RELEASE IGI Announces CRADA with National Cancer Institute to Test Proprietary Oral Cbl/b Inhibitor Treatment in Triple Negative Breast Cancer - Casitas B-lineage lymphoma…
DATE: 11 September 2024 CATEGORY: PRESS RELEASE IGI Announces Publication in Nature Cancer on ISB 2001, IGI's Innovative Trispecific Antibody for Relapsed/Refractory Multiple Myeloma - Article highlights preclinical findings demonstrating…
DATE: 30 Jan 2024 CATEGORY: PRESS RELEASE Ichnos and Glenmark take a collaborative leap to accelerate innovation in Cancer Treatment with their alliance - ‘Ichnos Glenmark Innovation’ FOR IMMEDIATE RELEASE…
DATE: 04 Jun 2021 CATEGORY: PRESS RELEASE chnos Sciences Presents Preclinical Data Confirming Potential for ISB 1342 in Relapsed/Refractory Multiple Myeloma at 2021 ASCO Annual Meeting ISB 1342 IS A…
DATE: 06 Aug 2021 CATEGORY: PRESS RELEASE Ichnos Sciences Nominates Innate Modulator ISB 1442 as Next Clinical Candidate for Treatment of Relapsed/Refractory Multiple Myeloma ISB 1442 IS A FIRST-IN-CLASS CD38…
DATE: 11 Dec 2021 CATEGORY: PRESS RELEASE Ichnos Sciences Presents Preclinical Data On Novel ISB 1442 In Relapsed/Refractory Multiple Myeloma At The ASH 2021 Annual Meeting ISB 1442 is a…
DATE: 14 Dec 2021 CATEGORY: PRESS RELEASE Ichnos Sciences and Almirall Enter Into a Licensing Agreement for First-In-Class IL-1RAP Antagonist Monoclonal Antibody Almirall is Granted Exclusive Global Rights to Develop…
DATE: 18 Mar 2022 CATEGORY: PRESS RELEASE Ichnos Sciences Presents Preclinical Data Package on First-in-class Oncology Treatment, ISB 1442, at IO360 Conference [FOR IMMEDIATE RELEASE]NEW YORK, NYMARCH 18, 2022NEW YORK,…
DATE: 23 Mar 2022 CATEGORY: PRESS RELEASE Ichnos Sciences Announces Presentation Of Additional Preclinical Data on ISB 1442 For Relapsed/Refractory Multiple Myeloma at AACR 2022 Annual Meeting ISB 1442 is…
DATE: 09 May 2022 CATEGORY: PRESS RELEASE Ichnos Sciences Announces Selection of Trispecific Antibody ISB 2001 as Next Clinical Candidate for Relapsed/Refractory Multiple Myeloma First TREAT™ Trispecific Antibody Targeting BCMA and…
